Ajinomoto Bio-Pharma expands small molecule manufacturing capabilities in India
The new 8,500 sq metre facility in Visakhapatnam is expected to be completed mid-2022
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
API
Govt may allow 30 per cent import of chemicals/intermediates in PLI scheme
In the next phase of the PLI scheme, the government has plans to incentivise excipient manufacturers
FDI in pharma and related implications of COVID-19
Arvind Sharma, Partner - M&A and General Corporate, Shardul Amarchand Mangaldas & Co states that the pharma sector is well…
DoP to finalise guidelines to select locations of three bulk drug parks and four med devices parks:…
Govt of Punjab shows interest in extending support for the development of bulk drugs park in the State
Local API production in India for COVID-19 repurposed drugs may offer competitive advantage:…
The advantages will be in terms of supply and price for the formulations manufactured in India, be it remdesivir, favipiravir or…
Pharma industry requests time-bound amendments in DPCO 2013
The industry specifically appealed for amendments in Para 13 (2) and Para 15 (6) of DPCO 2013 to overcome the challenge of surging…
CDSCO to assess issues in the procurement and prices of APIs
This step is being taken by the authorities after media reports and representation by different pharma associations raise concerns…
Hydroxychloroquine consignment from India arrives in the US
The US has bought more than 29 million doses of hydroxychloroquine for COVID-19 patients
China’s recovery from COVID-19 should not tempt us to take the easy way out again
One silver lining of the COVID-19 infection is that policy decisions have been fast tracked
Government asks MoEFCC to expedite clearance of API/intermediates
It is an interim measure taken by the central government to ensure that all necessary projects or activities in respect of bulk…